Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Dec. 31, 2017	Sep. 30, 2017
Current Assets:
Cash and cash equivalents	$ 7,370,697	$ 3,204,108
Prepaid expenses	110,817	220,246
Total Current Assets	7,481,514	3,424,354
Property and Equipment, Net of Accumulated Depreciation of $8,054 and $7,412	2,594	3,236
Other Assets:
Deposits	2,167	2,167
In-process research and development	19,400,000	19,400,000
Goodwill	1,586,796	1,586,796
Total Other Assets	20,988,963	20,988,963
Total Assets	28,473,071	24,416,553
Current Liabilities:
Accounts payable	561,160	602,431
Accrued expenses	616,213	560,918
Accrued compensation	1,203,376	1,063,000
Accrued interest - related parties	45,401	42,209
Notes payable - related parties	172,970	172,970
Due to related party	17,637	27,637
Total Current Liabilities	2,616,757	2,469,165
Commitments and Contingencies
Stockholders' Equity:
Preferred stock - $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding
Common stock - $0.001 par value; 200,000,000 shares authorized; 9,975,518 and 8,345,844 shares issued and outstanding at December 31, 2017 and September 30, 2017, respectively	9,976	8,346
Additional paid-in capital	56,813,704	49,660,242
Accumulated deficit	(30,967,366)	(27,721,200)
Total Stockholders' Equity	25,856,314	21,947,388
Total Liabilities and Stockholders' Equity	$ 28,473,071	$ 24,416,553

Amount of in process research and development.

No definition available.

Name:	ctxr_InProcessResearchAndDevelopment
Namespace Prefix:	ctxr_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).